Almac Discovery and Elasmogen to share Anti-ROR-1 VNAR data

Almac Discovery and Elasmogen, a biotech company developing next generation therapeutic biologics, have announced they will present a poster on their VNAR-based protein drug conjugates research targeting ROR1 at the upcoming American Association of Cancer Research (AACR) Meeting in Atlanta, Georgia from 29 March to 3 April 2019.

Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Elasmogen have been developing the use of VNARs as targeted oncology therapeutics with the aim of engineering superior anti-ROR-1 protein drug conjugate formats.

The poster presentation will highlight some initial work demonstrating the versatility of the VNAR platform and the suitability of ROR-1 as a target for these unique protein drug conjugates.

The presentation will be made by Almac Discovery’s Dr. Graham Cotton, Head of Protein Therapeutics:

Title: Novel protein drug conjugates targeting ROR1 through the development and exploitation of a drug discovery platform based on small, engineered VNAR domains

Presenting Author: Dr. Graham Cotton

Session: Antibody-drug Conjugates: New Agents and Technologies

Abstract Number: 2854

Location: Exhibit hall B, poster section 9, poster board number 13 - Georgia World Congress Centre

Date and Time: 31 March from 1-5pm

Permanent Abstract Number: 222

A copy of the poster will be made available on the Almac Discovery website immediately after the event.

Featured Companies

Almac Group (more information, website)

See also